We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-7.4%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.38B
AUM Growth
-$480M
Cap. Flow
+$130M
Cap. Flow %
2.42%
Top 10 Hldgs %
41.73%
Holding
224
New
23
Increased
133
Reduced
36
Closed
13

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$23.8M
2
GKOS icon
Glaukos
GKOS
+$20.8M
3
ARVN icon
Arvinas
ARVN
+$19.8M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
5
PACB icon
Pacific Biosciences
PACB
+$13.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$72.6M
2
GILD icon
Gilead Sciences
GILD
+$33.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$23.2M
4
TDOC icon
Teladoc Health
TDOC
+$19.5M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.28%
2 Industrials 0.53%
3 Technology 0.51%
4 Financials 0.07%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BKNG icon
201
Booking.com
BKNG
$139B
$393K 0.01%
5,000
+950
+23% +$73.6K
MSCI icon
202
MSCI
MSCI
$45.6B
$389K 0.01%
1,786
– –
TCOM icon
203
Trip.com Group
TCOM
$27.8B
$384K 0.01%
13,100
+4,068
+45% +$143K
SBUX icon
204
Starbucks
SBUX
$119B
$383K 0.01%
4,334
– –
KOS icon
205
Kosmos Energy
KOS
$1.37B
$374K 0.01%
60,000
– –
BLKB icon
206
Blackbaud
BLKB
$1.48B
$371K 0.01%
4,107
– –
AZPN
207
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$369K 0.01%
3,000
– –
LIN icon
208
Linde
LIN
$238B
$358K 0.01%
+1,848
New +$358K
STML
209
DELISTED
Stemline Therapeutics, Inc.
STML
$328K 0.01%
+31,500
New +$412K
ALXN
210
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$113K ﹤0.01%
+150
New +$16.9K
CVET
211
DELISTED
Covetrus, Inc. Common Stock
CVET
$18K ﹤0.01%
1,520
– –
AFMD
212
DELISTED
Affimed
AFMD
– –
-16,750
Closed -$481K
ANAB icon
213
AnaptysBio
ANAB
$1.6B
– –
-17,000
Closed -$959K
BIS icon
214
ProShares UltraShort NASDAQ Biotechnology
BIS
$2.24M
– –
-3,125
Closed -$426K
BLUE
215
DELISTED
bluebird bio
BLUE
– –
-1,405
Closed -$2.31M
CRM icon
216
Salesforce
CRM
$140B
– –
-1,956
Closed -$297K
FOLD
217
DELISTED
Amicus Therapeutics
FOLD
– –
-150,000
Closed -$1.87M
MELI icon
218
Mercado Libre
MELI
$93.5B
– –
-835
Closed -$511K
RARE icon
219
Ultragenyx Pharmaceutical
RARE
$2.87B
– –
-22,800
Closed -$1.45M
USB icon
220
US Bancorp
USB
$98.7B
– –
-5,662
Closed -$297K
VKTX icon
221
Viking Therapeutics
VKTX
$4.31B
– –
-96,000
Closed -$797K
CSLT
222
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-800,000
Closed -$2.58M
WCG
223
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-4,851
Closed -$1.38M
AVDR
224
DELISTED
Avedro, Inc Common Stock
AVDR
– –
-804,379
Closed -$15.8M
5 6 7 8
9

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2019 Portfolio in Review

As of Q3 2019, Bellevue Group held 224 positions worth $5.38B, down 8.2% from $5.86B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group's Q3 2019 filing shows 23 new, 133 increased, 36 reduced and 13 closed positions. Its largest new stake was Arvinas: 806,403 shares worth $17.4M. The largest sale was Celgene Corp, an estimated $72.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2019 buy was Arvinas: 806,403 shares worth $17.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2019, an estimated $23.8M increase.
  • Bellevue Group's biggest Q3 2019 reduction was Celgene Corp, cutting an estimated $72.6M.
  • Bellevue Group fully exited Avedro, Inc Common Stock in Q3 2019, selling an estimated $15.8M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.38B portfolio in Q3 2019.
  • Bellevue Group opened 23 new positions and closed 13 in Q3 2019.
  • Bellevue Group's portfolio value fell 8.2% quarter-over-quarter to $5.38B.

Based on Bellevue Group's 13F filing for Q3 2019, filed 14 Nov 2019.